Information om förpackningar av Metoject® (metotrexat)

Till följd av att allt fler användare av parenteralt metotrexat föredrar att använda Metojectpen® (förfylld injektionspenna) istället för Metoject® (förfylld spruta), anpassar Medac sig nu genom att minska ner antalet förpackningar av sprutorna, framför allt av de doser som börjar bli små i volym.

De förpackningar/doser som nu successivt tas ur sortimentet är;

Fortsatt kommer vi självklart att ha fullt sortiment av Metojectpen® (7,5 mg-30 mg).

Har du frågor eller funderingar, vänligen kontakta Peter Larsson eller Samira Nyman.





Press release – Medac at the EADV Congress

Real-life data demonstrate the potential of methotrexate in severe and moderately severe psoriasis

First French guidelines for psoriasis therapy – subcutaneous MTX is First-Line

Paris / Wedel (14 September 2018). Methotrexate (MTX) is established and proven as an effective systemic first-line therapeutic agent in the treatment of psoriasis.1  MTX is and remains the world’s most widely used systemic therapy, even despite new active substances entering the market. With the presentation of yet unpublished study data at the Medac-sponsored symposium, this year’s EADV Congress in Paris once again confirms the importance of methotrexate as the first-line treatment of moderately severe to severe psoriasis.

Click here to view full Press release


Press release – First marketing authorisation worldwide for methotrexate in moderate psoriasis

Medac’s marketing authorisation extension gives many patients with psoriasis access to guidelines-based MTX therapy for the first time.

Click here to view full Press release

Press release – Alacare®

Innovative therapeutic for the treatment of mild actinic keratoses –
first self-adhesive patch for PDT

  • The skin lesion actinic keratosis is associated with an estimated prevalence of up to 60 % in certain populations and bears a high disease burden being considered as precancerous
  • The treatment option with the ALA-PDT patch has not only been proven to be very easy to use and time-saving, but also to be more effective compared to cryotherapy regarding clearance rates, recurrences and pigmentation disorders
  • The first medical patch Alacare® has been launched first in Sweden and will be available in the United Kingdom, Denmark, Finland, Norway and Poland at the beginning of next year. Further countries will follow

Click here to view full Press release

Click here to view FactSheet